NEWS & INSIGHTS

https://www.irishtimes.com/business/technology/atxa-therapeutics-looks-to-raise-30m-to-secure-regulatory-approval-1.4314023

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a preclinical model of pulmonary arterial hypertension (PAH). These key findings show how NTP42 and antagonism of the thromboxane signalling pathway have a relevant role...

The companies driving Ireland's entrepreneurial edge.

ATXA Therapeutics Ltd is delighted to be recognised amongst such a fantastic list of Irish entrepreneurial companies.

https://user-twgplnu.cld.bz/100

We’re here at the ERS Congress 2019 where we will be presenting the our preclinical findings of NTP42 for the treatment of PAH. Please stop by the poster area at 2.45pm next Tuesday 1st October 2019.

We're here! Drop by the Poster Area for the session on "Pulmonary Arterial Hypertension ‑ Treatments" and talk to us about our preclinical results for NTP42.

ATXA Therapeutics and PAH-Hope team members, Prof. Therese Kinsella & Dr. Helen Reid are looking forward to the ESC Congress 2019 next week. They will be onsite presenting preclinical findings of NTP42 for the treatment of PAH (Pulmonary Arterial Hytertension).

ESC Cong...

Use the link below to read or download ATXA Therapeutics published article on the expression and regulation of thromboxane receptors in chronic inflammation within the prostate.

No sign up, registration or fees are required before September 06, 2019.

https://authors.else...